PATIENTS: 1) Forty-eight OHPs (M/F:33/15; median age yrs:65; range 29-82) were studied: 28 non Hodgkin lymphoma (NHL), 1 Hodgkin lymphoma (HL), 9 chronic lymphocytic leukemia (CLL), 10 multiple myeloma (MM). All were screened, before starting chemoth., for HBsAg, HBsAb, HBcAb, HCV-Ab, HAV-Ab and ALT values. HBsAg and ALT were monthly monitored and serum HBV-DNA was tested every 3 m after the start of chemoth. 2) Eleven pts. with HBV reactivation. RESULTS: Following serological

screening pts. were distinguished in 2 groups. Group A including 9/48 (1 8%) pts. (M/F:7/2; median age: 67 yrs (34-71) which resulted HBsAg/HBV-DNA pos (2 HBeAg+, 7 HBeAg-). One Rucaparib of these was HCV-Ab/HCV-RNA pos and all were HAV-Ab (IgG) pos. Group B including 39/48 (82%) HBsAg neg pts. (M/F: 26/13; median age yrs:65; range 29-82). Nine of 39 (23%) presented isolated HBcAb positivity and 29/39 (74%) HBsAb/HBcAb positivity. Five of 39 (13%) were HCV-Ab pos and 38/39 (99%) HAV-Ab (IgG) pos. Group C: 12 pts. (M/F: 7/5; median age 68 yrs), 7 with severe clinical selleck chemicals reactivation (jaundice and high ALT levels) and 5 with mild/moderate disease. 4 pts. were HBsAg neg/HBV-DNA pos. Standard therapy: Group A pts. (4 inactive and

5 active carriers) received antiviral therapy (5 entecavir (Ent) 0.5 mg/d, 3 Lam 100 mg/d, 1 Lam+adefovir); all cleared HBV-DNA (median time months:1 1; range 4-24), normalized ALT and completed chemoth. but are still HBsAg+. Lam prophylaxis: 上海皓元医药股份有限公司 Group B pts. started Lam 1 00 mg/d for 1 8

m after the last chemoth. Twenty of 39 (51%) pts. completed 1 8 m of Lam prophylaxis and 14/20(70%) passed 12 m after discontinuation of Lam prophylaxis. Median time after discontinuation of chemoth. and Lam is 30m (1-58) and 19m (1-54) respectively. None case of HBV reactivation has been observed. Five pts. of Group B died because hematologic malignancy. Rescue therapy: Group C pts. received Ent (7) and Lam (5). Two died because liver failure, 3 because hematologic disease; 7/1 1 cleared HBV-DNA and 3 returned HBsAg neg, 4 are still under treatment CONCLUSIONS: HBV reactivation is life threatening condition and must be prevented. Prolonged 18 months Lam prophylaxis is safe and effective in preventing HBV reactivation and in completing chemotherapy. Disclosures: The following people have nothing to disclose: Aldo Marrone, Mariarosaria Esposito, Chiara D’Amore, Isabella Siniscalchi, Romina Salpini, Marco Ciotti, Massimo CIccozzi, Carlo Federico Perno, Lucia Mastrullo Background: Chronic hepatitis delta virus (HDV) infection results in an accelerated course of liver disease and the only proven effective treatments for HDV (standard and pegylated inter-feron-alpha [pIFN]) result in a limited rate (~23%) of sustained response (SR). There is little information on the kinetics of loss of HDV RNA, HBV DNA and HBsAg during IFN therapy.